Lung cancer now also has a form of immunotherapy, which is really expensive, mainly applying PD-1 and PD-L1 inhibitors, both of which are currently available in China, and the specific cost may be 50,000-70,000 RMB per course of treatment. Immunotherapy for lung cancer is generally applied to second or third line treatment after chemotherapy and targeted therapy have failed. Lung cancer is a very common malignant tumor in the respiratory system, and the most commonly used methods are surgery, radiotherapy, chemotherapy, targeted therapy and other anti-tumor treatments. If conventional anti-tumor therapy is not effective or resistant, and there is no other way, choosing immunotherapy can also prolong survival. At present, with the entry of these drugs into medical insurance and the listing of domestic PD-1 inhibitors, the price will drop significantly, bringing more choices for patients’ treatment.